Nasstasja Wassilew

Primary Bedaquiline-Resistant Tuberculosis in an Afghan Migrant to Switzerland: Diagnostic and Treatment Challenges in a High-Resource Setting.

Bedaquiline, classified as a WHO 2019 group A drug, is a core component of BPaLM, revolutionizing the treatment of MDR/RR tuberculosis (TB). Since 2015, however, concerns about acquired and primary bedaquiline resistance have emerged. We report a diagnostically challenging case o...